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Abstract The ATP-binding cassette efflux transporter
P-glycoprotein (P-gp) is notorious for contributing to mul-
tidrug resistance in antitumor therapy. Due to its expression
in many blood-organ barriers, it also influences the phar-
macokinetics of drugs and drug candidates and is involved in
drug/drug- and drug/nutrient interactions. However, due to
lack of structural information the molecular basis of ligand/
transporter interaction still needs to be elucidated. Towards
this goal, a series of Benzopyranes and Benzopyrano
[3,4b][1,4]oxazines have been synthesized and pharmaco-
logically tested for their ability to inhibit P-gp mediated
daunomycin efflux. Both quantitative structure–activity
relationship (QSAR) models using simple physicochemical
and novel GRID-independent molecular descriptors
(GRIND) were established to shed light on the structural
requirements for high P-gp inhibitory activity. The results
from 2D-QSAR showed a linear correlation of vdW surface
area (A˚2) of hydrophobic atoms with the pharmacological
activity. GRIND (3D-QSAR) studies allowed to identify
important mutual distances between pharmacophoric fea-
tures, which include one H-bond donor, two H-bond
acceptors and two hydrophobic groups as well as their dis-
tances from different steric hot spots of the molecules.
Activity of the compounds particularly increases with
increase of the distance of an H-bond donor or a hydrophobic
feature from a particular steric hot spot of the benzopyrane
analogs.





ABC ATP binding cassette
QSAR Quantitative structure–activity relationship
GRIND GRID-independent molecular descriptors
MIF Molecular interaction field
Introduction
Development of multidrug resistance (MDR) is one of the
major challenges in cancer chemotherapy, as it limits the
effectiveness of many clinically important agents [1]. One
of the basic underlying mechanisms is overexpression of
the mdr1 gene product, P-glycoprotein (P-gp) [2], which
belongs to the ATP-binding cassette (ABC) family of
transporters [3]. It is highly promiscuous in its ligand
recognition profile and thus transports a large variety of
structurally and functionally diverse compounds out of
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tumor cells [4]. Apart from its role in tumor cells it is
expressed at epithelial cells of liver, kidney, intestine and
colon, as well as at the blood brain barrier. Thus, P-gp not
only plays an important role in maintaining a concentration
gradient of toxic compounds at these physiological barri-
ers, but also modulates the pharmacokinetics of drugs that
are recognized as P-gp substrates.
Within the past decade numerous inhibitors of P-gp med-
iated drug efflux have been identified [3]. Several compounds
entered even phase III clinical studies, such as MS-209
(dofequidar fumarate), tariquidar, valspodar and elacridar
[5, 6]. However, none made it to the market so far, mainly
because of lack of efficacy or severe side effects. In light of our
extensive SAR and QSAR studies of propafenones [7, 8],
benzophenones [9] and dihydrobenzopyrans [10], a new class
of conformationally restricted benzopyrano[3,4b][1,4]oxa-
zines have been synthesized and biologically tested with
respect to their ability to block P-gp mediated daunomycin
efflux. These new P-gp inhibitors offer the advantage of a
remarkably reduced conformational flexibility, which renders
them versatile molecular tools for probing stereoselective
differences of drug/P-gp interaction [11], as well as for
3D-QSAR studies. These might be performed by utiliz-
ing alignment-dependent approaches, such as CoMFA
and CoMSIA, or by alignment independent methods using
descriptors derived from Molecular Interaction Fields (MIFs),
like the GRIND [12]. In particular, the latter allow the analysis
of structurally diverse data series. GRID MIFs [13] have been
applied to many areas of computational drug discovery,
including 3D-QSAR [14], docking [15], high-throughput
virtual screening [16], ADME profiling, kinetic [17, 18] and
metabolism prediction [19] of early drug candidates. In this
manuscript we explore the capability of the GRIND approach
to derive predictive 3D-QSAR models for a set of diastereo-
meric benzopyrano[3,4b][1,4]oxazines. The GRIND based
3D-QSAR models added value in recognition of important
pharmacophoric features and their mutual distances. In
addition, molecular shape of the P-gp inhibitors has been




Synthesis of the benzopyrane common scaffold was achieved
in analogy to the procedure reported by Godfrey et al. [20] and
following our strategy outlined recently [11]. Besides a set of
diastereomeric esters and benzopyrano[3,4b][1,4]oxazines,
also a set of corresponding ethers were synthesized. Respec-
tive procedures and experimental details are provided in the
supplementary material. In general, compounds showing
4aS,10bR stereochemistry are denoted as (a)-series, whereas
the respective 4aR,10bS-analogues are assigned as (b)-series
(Table 1).
Calculation of physicochemical parameters
Hansch analysis
Molecular descriptors supplied by the program MOE (atom
and bond counts, connectivity indices, partial charge
descriptors, pharmacophore feature descriptors, logP (o/w),
calculated physical property descriptors) were computed
for Hansch analysis. QSAR-Contingency [21], a statistical
application in MOE, was used for the selection of relevant
descriptors. PLS analysis was performed to determine the
relationship between these 2D molecular descriptors and
biological activity of the compounds. The predictive ability
of the model was determined by classical leave one out
(LOO) and leave one pair out cross validation procedures
(SM Table 1). In order to remove any bias, the final model
was externally validated by using a test set of already
published dihydrobenzopyrans [10].
GRIND
3D conformations of the molecules in the data set were
obtained from their 2D coordinates by using the program
CORINA [22]. Molecular Interaction Fields (MIF) were
calculated as GRID based fields in Molecular Discovery
software Pentacle [23] using four different probes: DRY
probe to represent hydrophobic interactions, O sp2 carbonyl
oxygen probe to represent H-bond donor feature of the
molecules, N1 probe to represent –NH which is a neutral flat
probe as an H-bond acceptor in the molecules and the TIP
probe that represents the shape of the molecule, in terms of
steric hot spots. The regions with the most relevant MIF were
extracted by applying the AMANDA algorithm [24] that
uses the intensity of the field at a node and the mutual node–
node distances between the chosen nodes. At each point,
the interaction energy (Exyz) was calculated as a sum of









Default values of probe cutoff (DRY = -0.5, O = -2.6,
N1 = -4.2, TIP = -0.74) was used for discretization of
MIF. Nodes with an energy value below this cutoff were
discarded. The Consistently Large Auto and Cross
Correlation (CLACC) algorithm [23] was used for
encoding the prefiltered nodes into GRIND thus producing
most consistent variables as compared to MACC [25]. The
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values obtained from this analysis were represented directly
in correlogram plots, where the product of node–node
energies is reported versus the distance separating the nodes.
Highest energy product can be defined for the same probe
(obtaining four auto correlograms: DRY–DRY, O–O,
N1–N1 and TIP–TIP) and for pairs of different probes
(obtaining six cross correlograms: DRY–O, DRY–N1,
DRY–TIP, O–N1, O–TIP, and N1–TIP). The QSAR model
was built using PLS and its quality assessed by means of q2
and standard deviation error of prediction (SDEP). Classical
leave one out (LOO) method was applied to calculate q2
values. The final model was validated by leave one pair out
Table 1 Enantiomerically pure benzopyrano [3,4b][1,4] oxazines (5a–22b) and their IC50 values
# Scaffold Stereochemistry R1 R2 IC50 lM ± SD LogP(o/w)
5a (A) (3S,4R) (L) CH3 H 29.85 ± 0.01 2.84
5b (A) (3R,4S) (L) CH3 H 14.55 ± 0.05 2.84
6a (A) (3S,4R) (L) CH(CH3)2 H 2.40 ± 0.03 3.82
6b (A) (3R,4S) (L) CH(CH3)2 H 2.70 ± 0.02 3.82
7a (A) (3S,4R) (L) CH2(C6H5) H 0.55 ± 0.02 4.38
7b (A) (3R,4S) (L) CH2(C6H5) H 0.77 ± 0.04 4.38
8a (A) (3S,4R) (L) CH3 CH3 3.96 ± 0.06 3.11
8b (A) (3R,4S) (L) CH3 CH3 3.72 ± 0.03 3.11
9a (A) (3S,4R) (L) CH(CH3)2 CH3 0.96 ± 0.06 4.08
9b (A) (3R,4S) (L) CH(CH3)2 CH3 1.35 ± 0.003 4.08
10a (A) (3S,4R) (D) CH(CH3)2 H 4.62 ± 0.31 3.81
10b (A) (3R,4S) (D) CH(CH3)2 H 1.34 ± 0.08 3.81
11a (A) (3S,4R) (D) CH(CH3)2 CH3 1.01 ± 0.02 4.08
11b (A) (3R,4S) (D) CH(CH3)2 CH3 1.00 ± 0.05 4.08
12a (B) (2S,4aS,10bR) CH3 H 1241.6 ± 0.04 1.98
12b (B) (2S,4aR,10bS) CH3 H 76.89 ± 0.06 1.98
13a (B) (2S,4aS,10bR) CH(CH3)2 H 15.32 ± 0.32 2.94
13b (B) (2S,4aR,10bS) CH(CH3)2 H 59.33 ± 0.60 2.94
14a (B) (2S,4aS,10bR) CH2(C6H5) H 2.68 ± 0.18 3.51
14b (B) (2S,4aR,10bS) CH2(C6H5) H 259.78 ± 0.06 3.51
15a (B) (2S,4aS,10bR) CH3 CH3 47.83 ± 0.91 2.24
15b (B) (2S,4aR,10bS) CH3 CH3 28.93 ± 0.15 2.24
16a (B) (2S,4aS,10bR) CH(CH3)2 CH3 47.51 ± 0.40 3.21
16b (B) (2S,4aR,10bS) CH(CH3)2 CH3 16.70 ± 0.20 3.21
17b (B) (2R,4aR,10bS) CH(CH3)2 H 9.63 ± 0.08 2.95
18a (B) (2R,4aS,10bR) CH(CH3)2 CH3 79.27 ± 0.05 3.22
18b (B) (2R,4aR,10bS) CH(CH3)2 CH3 27.84 ± 0.02 3.22
19a (C) (2S,3S,4R) – H 54.05 ± 0.31 2.14
19b (C) (2S,3R,4S) – H 102.64 ± 0.15 2.14
20a (C) (2S,3S,4R) – CH3 5.46 ± 0.24 2.14
20b (C) (2S,3R,4S) – CH3 6.84 ± 0.15 2.14
21a (D) (2S,4aS,10bR) – H 48.80 ± 0.09 3.10
21b (D) (2S,4aR,10bS) – H 44.00 ± 0.03 3.10
22a (E) (2S,3S,4R) – CH3 35.22 ± 0.02 3.66
22b (E) (2S,3R,4S) – CH3 45.17 ± 0.05 3.66
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cross validation as already described in the 2D-QSAR
section (SM Table 2) as well as by an external test set
composed of previously published compounds.
Pharmacology
Biological activity of target compounds 5a–22b was asses-
sed using the daunorubicin efflux protocol as described
previously [26]. Briefly, multidrug resistant CCRF-CEM vcr
1,000 cells were incubated with daunorubicin and the
decrease in mean cellular fluorescence in dependence of
time was measured in presence of various concentrations
of the modulator. IC50 values were calculated from the
concentration–response curve of efflux Vmax/Km versus
concentration of the modulator. Thus, the effect of different
modulators on the transport rate is measured in a direct
functional assay. Values are given in Table 1 and are the
mean of at least three independently performed experiments.
Generally, inter experimental variation was below 20 %.
Results and discussion
Structure activity relationships (SAR)
Biological activity values of the data series cover a range of
more than three orders of magnitude (Table 1) with the
two phenylalanine esters 7a and 7b being the most active
compounds (7a: 0.55 lM; 7b: 0.77 lM), followed by
N-methylated L-valine analogues 9a (0.96 lM) and 9b
(1.35 lM), which are by a factor of 2 more active than the
corresponding unsubstituted analogs 6a (2.40 lM) and 6b
(2.70 lM). The same trend could be observed for the
respective D-valine derivatives. This observation is even more
pronounced for the alanine derivatives (compare methylated
analogs 8a (3.96 lM) and 8b (3.72 lM) versus respective
secondary amines 5a (29.85 lM) and 5b (14.55 lM). This
most probably is due to a logP effect with more lipophilic
compounds showing higher biological activity, which has
been shown for numerous classes of P-gp inhibitors [27].
It has to be noted that for all seven diastereoisomeric
pairs showing a bicyclic scaffold almost no differences in
biological activity exist. However, this pattern changes
remarkably upon ring closure to the tricyclic benzopyr-
ano[3,4b][1,4]oxazines. While all stereoisomers containing
a valine moiety (13a,b; 16a,b, 18a,b, 19a,b–22a,b) are still
within one order of magnitude, both the alanine and
phenylalanine derivatives exhibit remarkable differences in
their P-gp inhibitory potency (IC50) values. Interestingly, in
case of alanine, the 4aS,10bR-isomer 12a is by a factor of
15 less active than the diastereomeric 4aR,10bS analogue
12b, whereas in case of the phenylalanine derivatives this
behavior reverses with the 4aS,10bR-isomer 14a being by
two orders of magnitude more active than 14b. This dif-
ference in their biological activities might be due to dif-
ference in mode of interaction of diastereoisomeric pairs as
has been indicated in a preceding publication [11].
Hansch analysis
3D structures of all diastereoisomers were built with the
builder function of MOE 2011. 10 and energy minimised
using the MMFF94 force field which uses a bond charge
increment method to set the electrostatic partial charges
[28]. In order to determine the influence of physicochem-
ical properties of the compounds on their biological
activity, QSAR analyses were performed by using the
software package MOE version 2011. 10 and MOE’s
contingency analysis tool for identification of the most
important descriptors. The multiple linear regression
analysis produced an equation solely based on the hydro-
phobic van der Waals surface area (vsa_hyd) (Eq. 1).
Interestingly, descriptors related to electrostatic properties,
such as topological polar surface area and molar refrac-
tivity, did not show significant contributions to the model.
Log ð1=IC50Þ ¼ 0:01 ðvsa hydÞ  4:74 ð1Þ
n ¼ 35; R2 ¼ 0:67; q2ðLOOÞ ¼ 0:63; RMSE = 0:48
Figure 1 shows a plot of observed versus biological
activity predicted by QSAR E. 1. Compounds 14b and 22b
show outlier behaviour (residual value above one log unit).
Upon removal of these two compounds, the q2 value
improves to 0.70. Interestingly, both compounds belong to


























































Fig. 1 Plot of observed versus predicted MDR-modulating activity
expressed as log 1/IC50 (dashed line). Predicted values were obtained
with leave-one-out cross validation procedure. Results of linear
regression between observed and predicted log 1/IC50 values (dashed
line) and 1:1 line (continuous line) are shown on the plot for
comparative evaluation
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series additional factors other than lipophilicity might play
a role. Vsa_hyd describes the sum of van der Waals surface
areas of hydrophobic atoms (A˚2). This is perfectly in line
with previous studies which showed that distribution of
hydrophobicity within the molecules influences their mode
of interaction with P-gp [29] and lipophilicity needs to be
considered as a space directed property [30, 31]. This
space-directedness might be indicative for different
orientations of molecules within the binding area of P-gp,
which is mainly hydrophobic [32]. The QSAR model was
further validated by using an external test set of already
published dihydrobenzopyrans and tetrahydroquinolines
[10]. All compounds are predicted well, with the
residuals being less than one log unit from their
experimental inhibitory potencies (log IC50). This further
strengthens the reliability of the final QSAR model
(Table 2). Additionally, 18 different models were
developed by taking one pair of diastereoisomer out at
each step. All models showed q2 values in the range of
0.57–0.70, which further demonstrates the consistency of
the QSAR model (SM Table 1).
GRID Independent molecular descriptor (GRIND)
analysis
The previously computed molecular structures along with
their activity values (expressed as log1/IC50) were loaded
into the software package Pentacle (v 1.06) [23] to derive
3D-QSAR model using GRIND descriptors. According to
previous findings for propafenone analogs, all compounds
Table 2 Test set of dihydrobenzopyrans, their experimental and predicted inhibitory potencies (log1/IC50) by 2D-QSAR and GRIND models
# R1 Exp. log 1/IC50 Pred. log 1/IC50 (2D-QSAR) Pred. log 1/IC50 (GRIND) Log P(o/w)
1a -1.77 -1.38 -0.79 3.19
1b 0.19 -0.22 -0.11 2.98
1c -3.16 -2.35 -2.06 1.40
1d -1.67 -1.28 -0.77 2.38
1e -0.38 0.17 -0.27 4.43
2a -0.51 -0.34 -0.02 4.27
2b 0.37 0.80 0.28 4.07
2f -0.90 -0.57 -0.72 3.59
2g -0.29 1.07 -0.25 4.70
3f -0.75 -0.57 -0.77 4.34
3g 0.47 1.07 0.01 5.44
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were modeled in their neutral form [33]. Structural vari-
ance of the data was analyzed with principal component
analysis (PCA) performed on the complete set of GRIND
descriptors. The first two principal components explain
about 32 % of the descriptor variance in the data set.
Principal component analysis (PCA) on the data matrix
showed that the series is organized in three different
clusters (Fig. 2). Molecules in the cluster on the right hand
side (cluster 1) do not contain any H-bond donor, while the
second cluster (cluster 2) contains one H-bond donor
group. The 3rd cluster (cluster 3), located on the upper left
corner of the plot, contains compounds with two H-bond
donor groups in their structures. Furthermore, rigid and
smaller compounds (cluster 1 and cluster 2) are separated
from the flexible ones (cluster 3). Overall, compounds in
cluster 3 are more potent than compounds in cluster 1 and 2,
suggesting that an elongated structure is an important per-
quisite for high P-gp inhibitory potency.
In order to identify the more important pharmacophoric
features of ligand–protein interaction, a PLS model was
built, using the complete set of active variables (450)
generated by Pentacle (v 1.06). This resulted in a one-latent
variable (LV1) model with an r2 of 0.51 and a cross-vali-
dated (LOO) q2 value of 0.27, which was quite unsatis-
factory. Thus, variable selection was applied to reduce the
variable number using the FFD variables selection algo-
rithm [34] implemented in Pentacle. This resulted in a
decrease from 450 to 196 variables and a large increase of










































































































Fig. 3 Plot of observed versus predicted (LOO) MDR-modulating
activity (log1/IC50) of inhibitors of P-gp obtained with the GRIND
descriptors
Fig. 4 3D representatives of series (a) having 2S,4aS,
10bR-configuration and series (b) having 2S,4aR,10bS-configuration
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With the exception of compounds 14b, 5a, and 12a, all
compounds are within one order of magnitude from their
predicted values (14b: obs 259.78, pred 23.21; 5a: obs
29.85, pred 2.80; 12a: obs 1241.65, pred 58.30 lM)
(Fig. 3). The outlier behavior of these three compounds
might be due to potential different interaction behavior of
the two diastereomeric series as reported by Jabeen et al.
[11]. However, building two separate QSAR models
composed of compounds of series (a) and series (b) in two
separate training sets showed an analogous picture and did
not improve the results (data not shown). Thus, although
GRIND descriptors are able to capture different configu-
rations, they were not able to extract the differences of the
two diastereomeric series. This might be due to the fact that
the molecules are quite compact (Fig. 4) and GRIND is
considering MIFs within a grid step of 0.5 A˚.
All compounds of the external test set are predicted
within one log unit from the experimental inhibitory
potencies (log IC50), except (1c), where the residual is
slightly more than one log unit (Table 2). The low activity
of 1c mainly might be due to its low logP value, which is
not properly reflected in the GRIND based pharmacophoric
features. Thus, GRIND is over predicting the compound.
The overall good predictive ability and model statistics of
all 18 leave one pair out GRIND models further
demonstrates the consistency and validity of the GRIND
based 3D-QSAR model (SM Table 2).
Analysis of the PLS coefficients profile of the GRIND
model allows to identify those descriptors which exhibit
the largest contribution to the model. According to the
bar plot shown in Fig. 5, certain distances of the N1–N1,
O–N1, and O–TIP probes are participating most in explain-
ing the variance in the biological activity values (Table 3).
The sum of the van der Waals surface areas of hydro-
phobic atoms (vsa_hyd) has emerged as an important
determinant for high biological activity of benzopyrane-
type P-gp inhibitors (Eq. 1). The 3D-QSAR model using
GRIND descriptors further refines this general property and
identified two hydrophobic regions (DRY–DRY) separated
by a certain distance range in all active compounds. These
represent the aromatic ring of the benzopyrane ring sys-
tem and R1. In the most active phenylalanine derivatives
(7a,b and 14a,b) the two regions are separated by a dis-
tance of 13.2–13.6 A˚, which is considered optimal accord-
ing to the GRIND model. Thus, adding a large hydrophobic
group (large vsa_hyd) at the position of R1 might lead to a
further increase of the biological activity.
Previous QSAR studies on propafenone derivatives have
demonstrated the importance of H-bond acceptors and their
distance from the central aromatic ring [35, 36].
Fig. 5 PLS Coefficients
showing the descriptors directly
(positive value) or inversely
(negative values) correlated to
IC50. P-gp inhibitory potency
particularly increases with the
increase in (N1–N1), (O–N1)
and (O–TIP) descriptor value
Table 3 Summary of GRIND variables and their corresponding distances that are identified as being highly correlated to biological activity of
compounds 5a–22b
Correlogram Distance Comment
DRY–DRY 13.2–13.6 A˚ Optimal distance separating two hydrophobic groups. More pronounced in phenylalanine derivatives
N1–N1 8.8–9.2 A˚ Related to two hydrogen bond acceptor atoms in the molecules. This is mainly associated to
the carbonyl group and the hydroxyl groups in tert-butyl esters
O–N1 2.4–2.8 A˚ Well pronounced in tert-butyl esters with IC50 *1 lM. Positive contribution towards
P-gp inhibitory potency
O–N1 9.6–10.0 A˚ Complements N1–N1, contributing directly to the inhibition of P-gp mediated drug efflux
O–TIP 12.8–13.2 A˚ H-bond donor present far away from a steric hot spot, positive contribution to IC50
O–TIP 5.6–6.0 A˚ H-bond donor present quite near to a steric hot spot, contributing negatively
DRY–TIP 15.2–15.6 A˚ Complements to DRY–DRY correlogram, positive contribution to P-gp inhibitory potency
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Furthermore, Seelig [37, 38] more explicitly defined two
patterns of H-bond acceptor groups and their fixed spatial
distance observed in ligands of P-gp. Pattern I contains two
H-bond acceptors separated by a distance of 2.51 ± 0.30
A˚, while pattern II comprises two or three H-bond acceptor
groups at a distance of 4.60 ± 0.60 A˚ apart. Interestingly,
the 3D-QSAR model based on benzopyrano[3,4b][1,4]ox-
azines identified an optimal distance of 8.8–9.2 A˚ between
two H-bond acceptor groups (N1–N1) in all compounds
exhibiting IC50 *1 lM. The N1–N1 correlogram is mainly
associated to the carbonyl group and the hydroxy group in
tert-butyl esters 7a–11b. For tricyclic compounds (15a–16b
and 18a,b) it is associated to the distance of the carbonyl
group and the tertiary nitrogen atom. Finally, for amino
alcohols 19a–20b this descriptor refers to the two hydroxy
groups in the molecules. This indicates that the presence of
two H-bond acceptors is important for the biological activity
of P-gp inhibitors if they are separated by a distance
of *8.8–9.2 A˚ (Fig. 6a), which is in line with several
other studies. Crivori et al., used GRIND descriptors to
identify 3D pharmacophoric features which differentiate
P-gp inhibitors from substrates. They reported two H-bond
Fig. 6 a Represents two
H-bond acceptors (N1–N1: blue
hot spots) at a distance of
8.8–9.2 A˚. b DRY-TIP
represents a hydrophobic probe
(DRY: yellow hot spots) at a
distance of 15.2–15.6 A˚ from a
steric hot spot (TIP: green
region). c O–TIP outline an
H-bond donor (OH) (O: red hot
spots) at a distance of 12.8–13.2
A˚ from the 9-carbonitril edge’’
of the molecule. d Marks an
H-bond donor (–NH) at a
distance of 5.6–6.0 A˚ from the
9-carbonitril edge of the
molecule (O–TIP).
e Representing an H-bond donor
(OH) at a distance of 9.6–10.0 A˚
from an H-bond acceptor
(C=O), present only in esters
(O–N1). f Representing, H-bond
donor (–NH) at a distance of
2.4–2.8 A˚ from an H-bond
acceptor (C=O)
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acceptors at a distance of 8.0 A˚ apart from each other in
P-gp inhibitors [39], whereas a distance of 11.5 A˚ between
two H-bond acceptors, along with the importance of shape
descriptors, have been reported by Cianchetta et al. [40] for
substrates of P-gp.
However, despite of similarities in the number of
H-bond acceptors necessary for a high biological activity, a
direct comparison of distance matrices thereof across dif-
ferent chemical scaffolds reveals some differences. This
most probably is due to the fact that the large binding site
of P-gp has multiple spots able to contribute to H-bond
interactions and that different chemical series utilize dif-
ferent H-bond interaction patterns.
Apart from a certain number of H-bond acceptors, one
H-bond donor along with hydrophobic regions distribution
have been identified as important pharmacophoric features
of P-gp inhibitors/substrates [8, 36]. It is worth noting that
a very similar MIF based pharmacophore of P-gp inhibitors
was recently published by Broccatelli et al. [41]. They
identified one H-bond acceptor and two large hydrophobic
regions, together with an optimal molecular shape, as being
important for high activity, and successfully used their
model for virtual screening to identify new P-gp inhibitors.
The results are further in line with Boccard et al. [42]
outlining an optimal shape and hydrophobicity as major
physicochemical parameters responsible for the affinity of
flavonoid derivatives for P-gp [43, 44].
Also in our GRIND model, shape based probes (TIP)
defining steric hot spots exhibit a significant contribution.
Especially the 9-carbonitrile group in the benzopyrane scaf-
fold encodes an important molecular boundary (steric hot
spot) and serves as anchor for defining optimal distance ranges
to an H-bond donor (O–TIP correlogram) as well as to a
hydrophobic feature (DRY–TIP correlogram). The O–TIP
combination of probes encodes the shape of the molecules
(steric hot spots) together with an H-bond donor group.
Interestingly, O–TIP coefficients are negative for a distance
between 5.6 and 6.0 A˚, but become positive for larger dis-
tances (12.8–13.2 A˚). These distances (12.8–13.2 A˚) are
present in benzopyranes bearing tert-butyl esters (5a–11b)
and amino alcohol derivatives (19a–20b and 22a,b) as shown
in Fig. 6c. In tricyclic diastereoisomers (12a–14b and 17b)
these descriptors are linked to shorter distances and mark
(–NH) as an H-bond donor at a distance of 5.6–6.0 A˚ apart
from the cyano group, which is the main group contributing to
the TIP MIF, and seems to be related with a negative influence
for the biological activity of this group (Fig. 6d). This indi-
cates that, in general, the most potent P-gp inhibitors show
extended conformations and have an H-bond donor group far
from regions with a strong TIP probe related field.
Analyzing the DRY-TIP correlogram it becomes evident
that a hydrophobic group at a distance of 15.2–15.6 A˚ from
one of the ‘‘edges’’ of the molecule (steric hot spot, cyano
group) positively contributes to biological activity. In
tert-butyl esters (5a–11b) and 14a,b these two probes map
the distance between a hydrophobic group (R1) (14a,b) or
tert-butyl group in 5a–11b from the cyano group (Fig. 6b).
In analogy to the O–TIP correlogram, DRY–TIP shows a
negative contribution towards biological activity for
shorter distances (7.6–8.0 A˚) of these probes.
Finally, the O–N1 correlogram (H-bond donor–H-bond
acceptor) points towards two positive contributions at a
distance of 9.6–10.0 and 2.4–2.8A˚, respectively (Fig. 6e, f).
The first distance is linked to the hydroxyl and carbonyl
group in 5a–11b and is complementary to the N1–N1
correlogram as already discussed. The second distance
refers to the –NH and carbonyl group. O–N1 probes at both
distance ranges are well pronounced in tert-butyl esters
(5a–11b) as well as in amino alcohol substituted deriva-
tives (19a–20 b and 22a,b). However, in all tricyclic
compounds (12a–18b) the two probes do not fit either of
the distance ranges.
To summarize, the presence of two H-bond-acceptor
groups and one H-bond donor at a particular distance from
each other and from a particular ‘‘edge’’ or steric hot spot
of the molecule is associated to an increase of the biolog-
ical activity in benzopyrane-type P-gp inhibitors (Fig. 6).
Conclusions
Benzopyrano-[3,4b][1,4]oxazines are versatile molecular
tools for probing the stereoselectivity of P-glycoprotein.
For a distinct substitution pattern, different pairs of dia-
stereoisomers exhibit a large difference in their potency to
inhibit P-gp mediated drug efflux. Unfortunately, GRIND-
based 3D-QSAR models were unable to link these dif-
ferences to concrete differences of distances between
pharmacophoric hot spots, even if the GRIND analysis
provided a reasonably well performing 3D-QSAR model
outlining a set of important pharmacophoric features. Two
H-bond-acceptor groups, one H-bond donor at a particular
distance from each other as well as distinct distances of
these probes to steric hot spots seem to play a major role in
the interaction of benzopyrane-type P-gp inhibitors. The
activity particularly increases when increasing the distance
between an H-bond donor or a hydrophobic feature and a
particular steric hot spot of the benzopyrane analogs. This
not only further highlights the importance of H-bonding,
but also indicates that a certain shape/configuration of the
molecules is important for high activity. Further analyses
will focus on a generalisation of this finding in other series
of P-gp inhibitors.
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